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Can community volunteers work to trace patients defaulting 
from scheduled psychiatric clinic appointments?
David A Richards, Timothy J Bradshaw, Hilary Mairs, Essie Ricks, Johanita Strumpher, Nolan Williams, Rachel Richardson
To the Editor: Mental illness is set to become the second 
largest source of economic and social burden worldwide by 
2020.1 In many South African township communities, effective 
treatment is hampered because stretched professional staff are 
unable to follow up defaulting patients.2 Defaulting can have 
disastrous consequences for patient health, including treatment 
breakdown, imprisonment, death by suicide, harm to others, 
homelessness, relapse and re-hospitalisation.3
Many countries have employed ‘assertive outreach’ workers 
to address the negative consequences of defaulting. These 
workers enable patients to remain in contact with services, 
resulting in enhanced treatment compliance, improved 
employment status and greater patient satisfaction.4 In South 
Africa important public policy principles such as community 
involvement and the role played by volunteers in supporting 
family members and helping patients remain in treatment5 
must be incorporated into mental health assertive outreach 
systems, just as they have in key programmes such as directly 
observed treatment for tuberculosis and HIV/AIDS voluntary 
counselling and testing.
We report the results of a study assessing the feasibility of 
volunteers tracing patients who had defaulted from scheduled 
psychiatric clinic appointments. Volunteers were trained in 
the main features of mental health problems and equipped 
with the knowledge and skills to communicate effectively with 
people with mental health problems.6 Training materials are 
available at  www.who.int/mental_health/policy/education/en. 
Psychiatric clinic nurses identified patients who had 
defaulted from scheduled appointments. Volunteers were 
responsible for tracing these patients and encouraging them 
to return to the clinic as soon as possible. Volunteers either 
accompanied patients to the clinic or recorded patients’ 
decisions on a tracing slip – whether the patient agreed 
to return, was untraceable, had moved away, died, was in 
hospital or had another outcome. Nurses recorded when 
patients returned to the clinic. 
Volunteers traced 178 (84%) of 211 defaulting patients, of 
whom 120 (57%) subsequently returned to the clinic. The 
remaining 58 traced patients included those who had died or 
relocated, were in hospital or prison, or were treated at home, 
or where contact was made with a relative or caregiver only 
(Table I). Volunteers contacted 98% of traceable patients within 
3 days. A small number of patients were treated at home by 
clinic nurses who accompanied volunteers. Volunteers acted 
independently without professional support for 80% of visits. 
In 20% of cases volunteers assisted professional nurses to make 
contact with patients.
We have shown, therefore, that volunteers can make a major 
impact on defaulting rates in hard-pressed psychiatric clinics, 
through rapid tracing of patients who default from scheduled 
appointments. Most of the patients who did not return 
had died or moved away or were in institutions, valuable 
information previously unknown to the nurses running 
clinics. Nurses reported that they valued the assistance and 
feedback from volunteers, enabling them to provide effective 
and prompt attention to patients who would ordinarily be 
lost to their service. Volunteers mainly acted independently 
and reported gaining a significant sense of recognition and 
self-worth from their role. They also facilitated the nurses to 
work more effectively within the community, with nurses 
reporting feeling safer when visiting patients in the presence of 
a community volunteer. 
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Table I. Outcomes of patients in tracing programme
Outcome    N %
Returned to clinic   120   56.9
Relocated      22   10.4
Died      14     6.6
In hospital     12     5.7
In prison       2     0.9
Treatment given at home     6     2.8
Contact with caregiver/family only    2     0.9
Untraceable     33   15.7
Total    211 100.0
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Nurses reported that they most valued the system when 
the feedback they received was prompt and consistent, and 
when volunteers worked regularly and were well known to the 
nurses. It would seem to be important, therefore, to embed a 
supervision, management and support system in a community-
based organisation in order to ensure that volunteers continue 
to operate the system on a regular basis. This support could 
be offered by professionals and community volunteer co-
ordinators working together. 
It is now necessary to subject volunteer mental health 
outreach systems that integrate community volunteer health 
workers into mental health care systems to rigorous evaluation. 
Such studies should include assessment of patients’ clinical 
outcomes, long-term retention in services, costs, community 
impact and the sustainable management of volunteer 
programmes.
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Dandy-Walker variant in an infant prenatally exposed to 
antiretroviral medication
M F Urban, M F Chersich
To the Editor: We report a case of Dandy-Walker variant 
(DWV) in the infant of a 35-year-old woman who received 
treatment for human immunodeficiency virus type 1 (HIV) 
and tuberculosis. She received stavudine (D4T), lamivudine 
(3TC), nevirapine and cotrimoxazole throughout pregnancy, 
and isoniazid, rifampicin, pyrazinamide and ethambutol from 
before pregnancy until 29 weeks’ gestation, when DWV was 
detected on antenatal ultrasound. She had no history of genetic 
disorders, consanguinity, and alcohol or recreational drug use. 
Amniocentesis revealed a normal male karyotype. Serology 
for cytomegalovirus and toxoplasmosis did not indicate 
recent infection. The infant was full-term and appropriate 
for gestational age, with a normal head circumference, no 
dysmorphism, and no clinical features of HIV infection. 
Cranial ultrasound confirmed the presence of DWV and mild 
ventriculomegaly.  
DWV is part of a continuum of rare developmental 
abnormalities of the posterior brain fossa. It includes cystic 
dilatation of the fourth ventricle and partial agenesis of 
the cerebellar vermis. Only in a minority of cases is there a 
known cause, such as a chromosome abnormality or other 
genetic syndrome, or teratogen – especially alcohol. The 
developmental mechanism is unknown but relates to abnormal 
hindbrain development at 7 - 8 weeks’ gestation.1 Its prognosis 
varies from normality to severe neurodevelopmental delay 
with hydrocephalus.2 
The question arises as to whether the reported DWV 
represents a teratogenic effect of one or more of the maternal 
medications. We highlight deficiencies in the existing evidence.
The regulatory framework for assessing drug safety has not 
promoted optimal collection of information on teratogenicity. 
The most important authority regulating registration of new 
drugs is the United States Food and Drug Administration 
(FDA), from which other national registering agencies often 
take a lead. The FDA provides for assessment of drugs prior 
to approval for marketing and for post-marketing adverse 
event reporting. As pregnant women are not included in 
human clinical trials prior to FDA approval, assessment of 
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teratogenicity relies heavily on animal studies (that cannot 
give definitive information regarding risk in humans) and 
post-marketing surveillance. The post-marketing surveillance 
system was recently strongly criticised,3,4 particularly its over-
reliance on passive surveillance and retrospective data, and 
poor enforcement.
Teratogenicity data for antiretrovirals (ARVs) is better than 
for most drugs because an Antiretroviral Pregnancy Registry5 
aims to obtain prospective information. Although aiming to 
collect data worldwide, the registry suffers from substantial 
under-reporting, containing only 15% of US exposures and, 
so far, only about 50 ARV-exposed pregnancies in South 
Africa. Ascertainment of birth defects is also not standardised, 
with varying use of diagnostic tests and level of expertise 
of reporting clinicians. A further problem in assessing 
teratogenicity data is the complexity of collecting information 
on drug combinations. Whether combination therapy increases 
the risk of birth defects is unclear, but one study has raised this 
possibility for the combination of ARVs and cotrimoxazole.6 
Teratogenicity data collected elsewhere may not hold true for 
South Africans. An example of this is the unusually high rates 
of fetal alcohol syndrome in South Africa. This is not easily 
explained by alcohol consumption patterns, and aggravating 
factors related to poor socio-economic status have been 
implicated.7 
Regarding ARVs, most evidence for teratogenicity exists for 
efavirenz, which our patient did not receive. Efavirenz is an 
FDA category D drug, i.e. ‘Evidence of human fetal risk exists, 
but benefits may outweigh risks in certain situations’,8 owing 
to concerns that it may cause birth defects of the central 
nervous system, based on animal data and four retrospective 
case reports, including one infant with Dandy-Walker 
syndrome.9-12 The magnitude of risk with first-trimester 
exposure to efavirenz is unknown, and the four case reports 
may reflect background rates of birth defects. Prospective data, 
collected in the Antiretroviral Pregnancy Registry, indicates 
that the overall increased risk for birth defects among 
efavirenz-exposed infants is low: the rate of birth defects 
among infants with first-trimester efavirenz exposure was 2.4% 
(6 of 225 infants; 95% CI = 0.9 - 0.1%), compared with an 
expected rate of 3.1% (the background rate of congenital 
anomalies detectable at birth).5 
Our case of DWV is an infant prenatally exposed to a drug 
combination including ARVs, but not efavirenz. We highlight 
the limited nature of information available to support the fears 
regarding the teratogenicity of efavirenz, and the converse 
lack of concern regarding other combinations of ARVs and 
other drugs used in HIV-infected individuals. Although we 
support current guidelines to avoid efavirenz in reproductive-
age women not using contraception,13 the evidence indicates 
a low risk to an inadvertently exposed fetus and does not 
justify pregnancy termination based on the possible risk of 
teratogenesis. A fetal anomaly ultrasound scan at 18 - 23 
weeks’ gestation is recommended, and genetic counselling 
is advisable for women who are anxious or want further 
information. In view of the limited available information and 
the large numbers of reproductive-age women initiating highly 
active ARV therapy, there is an opportunity and a need to 
systematically collect local data.
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